Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)

• Tatiana Kharitonova,
• Yury G Shvarts,
• Andrey F Verbovoy,
• Natalia S Orlova,
• Valentina P Puzyreva,
• Igor A Strokov

Affiliations

Tatiana Kharitonova

Department of Acute Cerebrovascular Pathology and Emergency Neurology, Sankt-Peterburgskij naucno-issledovatel`skij institut skoroj pomosi imeni I I Dzanelidze, Sankt Peterburg, Russian Federation

Yury G Shvarts

Department of Faculty Therapy, City Clinical Hospital, Saratov, Russian Federation

Andrey F Verbovoy

Department of Endocrinilogy, Limited Liability Company ‘Center Diabetes’, Samara, Russian Federation

Natalia S Orlova

Endocrinologist, ‘Eco-Safety’ Medical Center, St Petersburg, Russian Federation

Valentina P Puzyreva

City Endocrinology Center, City Hospital No 4, Rostov-on-Don, Russian Federation

Igor A Strokov

Department of Nervous Diseases and Neurosurgery, Sechenov University, Moskva, Russian Federation